RedHill Biopharma Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

RedHill Biopharma hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	US$0.75
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

Jul 28

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Nov 24

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

Oct 18

RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Dec 02

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von RDHL in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von RDHL gestiegen sind.

Dividendenrendite im Vergleich zum Markt

RedHill Biopharma Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von RDHL im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (RDHL)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose in 3 Jahren (RDHL)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von RDHL im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von RDHL im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von RDHL, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da RDHL keine Ausschüttungen gemeldet hat.

RedHill Biopharma Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board

RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035

RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Full year 2023 earnings released: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $1.25 million.

New minor risk - Financial data availability

Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million.

RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million.

Investor sentiment deteriorates as stock falls 15%

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Investor sentiment deteriorates as stock falls 22%

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034

Investor sentiment improves as stock rises 615%

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034

RedHill Biopharma Ltd. announced that it has received $4.043808 million in funding

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Redhill Biopharma Ltd. Announces Fda Snda Approval for Talicia®?

RedHill Biopharma Ltd. Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA)

New minor risk - Earnings quality

Second quarter 2023 earnings released

RedHill Biopharma Ltd. Announces its Partner, Gaelan Medical LLC Receives Marketing Approval from United Arab Emirates Ministry of Health for Talicia

RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks

New major risk - Share price stability

RedHill Biopharma Ltd., Annual General Meeting, Aug 08, 2023

First quarter 2023 earnings released: EPS: US$20.00 (vs US$15.64 loss in 1Q 2022)

New major risk - Revenue and earnings growth

RedHill Biopharma Ltd. Provides R&D Update

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Redhill Biopharma Ltd. Announces Board Changes

Full year 2022 earnings released: US$48.00 loss per share (vs US$84.03 loss in FY 2021)

Redhill Biopharma Ltd. Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 for Oncology Support

RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome

RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

Redhill Biopharma Ltd. Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB 107 in Non-Hospitalized COVID-19

RedHill Biopharma Ltd. has completed a Composite Units Offering in the amount of $7.989775 million.

RedHill Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of $8 million.

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.46 loss in 3Q 2021)

One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts

Consensus forecasts updated

Redhill Biopharma Ltd. Announces Positive New Data with Opaganib for Nuclear Radiation Injury

Insufficient new directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

RedHill Biopharma Ltd. Provides Earnings Guidance for the Third Quarter Ended September 30, 2022

RedHill Biopharma Ltd. Presents New Talicia® Data Analyses At Obesity Week 2022

Insufficient new directors

Redhill Biopharma Ltd. Announces Presentation of New Data Analyses for Talicia

RedHill Biopharma Ltd. Announces Grant of New COVID-19 Treatment Patent for its Oral Broad-Acting Antiviral, Opaganib

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency

Redhill Biopharma Ltd. Announces Study Results Showing in Vitro Efficacy Against the Currently Dominant Omicron Covid-19 Sub-Variant BA.5

Insufficient new directors

RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease

Consensus forecasts updated

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.53 loss in 1Q 2021)

RedHill Biopharma Ltd. to Report Q1, 2022 Results on Jun 23, 2022

Price target decreased to US$13.60

RedHill Presents New Talicia Data Analyses at DDW 2022

RedHill: Given Up For Dead

Forecast breakeven date moved forward to 2023

RedHill Biopharma Ltd. Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

RedHill Biopharma Ltd., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

Price target decreased to US$14.14

RedHill Biopharma: Looking At An Unexciting Dead-End

RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI

RedHill Biopharma Ordinary Shares Deleted from Other OTC

RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven